GABRA1 and GABRB2 Polymorphisms are Associated with Propofol Susceptibility
Youjie Zeng,Si Cao,Minghua Chen,Chao Fang,Wen Ouyang
DOI: https://doi.org/10.2147/PGPM.S348170
2022-02-09
Pharmacogenomics and Personalized Medicine
Abstract:Youjie Zeng, 1 Si Cao, 1 Minghua Chen, 1 Chao Fang, 1, 2 Wen Ouyang 1 1 Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China; 2 Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China Correspondence: Wen Ouyang, Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China, Email Purpose: To explore the effect of gene polymorphisms of propofol GABA A receptor and metabolic enzyme on drug susceptibility during the induction period of general anesthesia. Patients and Methods: A total of 294 female patients aged 18– 55 years, ASA I–II, who underwent hysteroscopy with intravenous general anesthesia, were included in the study. Anesthesia was induced by continuous intravenous infusion of propofol at 40 mg·kg − 1 ·h − 1 . Infusion of propofol was ended when both the Modified Observer's Assessment of Awareness/Sedation scale (MOAA/S scale) decreased to 1 and the BIS index decreased to 60. The time when the MOAA/S scale decreased to 1 and the time when BIS index decreased to 60 was recorded to assess the susceptibility to the sedation effect. The maximum decreased percentage in mean arterial pressure (MAP) within 5 minutes was recorded to assess the susceptibility of cardiovascular response. Venous blood of each patient was collected to identify the presence of genetic variants in the GABRA1, GABRA2, GABRB2, GABRB3, GABRG2, CYP2B6 , and UGT1A9 genes using the Sequenom MassARRAY ® platform. Results: After receiving propofol infusion, carriers of polymorphic GABRA1 rs4263535 G allele required significantly less time for BIS decreased to 60, while carriers of polymorphic GABRB2 rs3816596 T allele required significantly more time for BIS decreased to 60, carriers of polymorphic GABRA1 rs1157122 C allele and carriers of polymorphic GABRB2 rs76774144 T allele had a significantly less change in MAP. Conclusion: GABRB2 rs3816596 and GABRA1 rs4263535 polymorphisms are associated with susceptibility to the sedation effect of propofol. GABRA1 rs1157122 and GABRB2 rs76774144 polymorphisms are associated with the degree of drop in blood pressure after propofol infusion. Keywords: pharmacogenomics, drug susceptibility, GABA A receptor, CYP2B6 , UGT1A9 Propofol is an intravenous anesthetic that is frequently used for induction of general anesthesia, maintenance of general anesthesia, sedation in the intensive care unit (ICU), and various painless treatments due to its advantages of rapid onset, rapid awakening, and low incidence of postoperative nausea and vomiting. 1 Despite the numerous advantages, propofol can still carry some side effects. Frequent adverse reactions are pain on injection, hypotension, and respiratory depression. 2 In addition, the drug effect of propofol varies with different individuals, even when administered by the same standard. 3 Deep anesthesia will excessively suppress the stress response, leading to severe hypotension and even disrupting the perfusion of vital organs, while inadequate depth of anesthesia will lead to an increased incidence of intraoperative awareness. Therefore, it is important to individualize the medication and give patients the most proper dose to maintain an appropriate depth of anesthesia. Propofol is mainly metabolized in the liver. 4 Seventy percent of propofol bound to uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9) and transform into propofol glucuronide, 29% of propofol is transformed into propofol-4-hydroxypropophol by CYP2B6 and CYP2C9, in which CYP2B6 plays a primary role and CYP2C9 a secondary role. 5 Propofol exerts its sedation effect mainly through activating the GABA A receptor (GABAAR), thereby enhancing the interaction between GABA A and GABAAR. 6 Pharmacogenomics focuses on the relationship between genetic factors and drug response variability. 7 Single nucleotide polymorphism (SNP) refers to a DNA sequence polymorphism caused by a single nucleotide variation that has a prevalence of more than 1% in the population. 8 Pharmacogenomics studies often concern the SNPs related to the pharmacodynamic and pharmacokinetic of certain drugs. Identifying SNPs associated with drug response can help reduce adverse drug reactions, particularly important in patients with poor general conditions. 9</su -Abstract Truncated-
pharmacology & pharmacy